Uğur ÖNAL, Esma PEHLİVAN, Mehmet Sezai TAŞBAKAN, MELTEM TAŞBAKAN, Oğuz REŞAT SİPAHİ, Tansu YAMAZHAN

ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ SONRASI CMV PNÖMONİSİ: OLGU SUNUMU

Allojenik kök hücre nakli sonrası başta pnömoni olmak üzere sitomegalovirüs (CMV) infeksiyonları sık görülmekte olup önemli bir mortalite ve morbidite sebebidir. Bu yazıda primer myelofibrozis tanısı nedeniyle allojenik kök hücre nakli yapılan ve sonrasında "Graft versus Host Disease" gelişen 45 yaşında bir erkek hasta sunulmaktadır. Hasta, kök hücre naklinden sonra aralıklı proflaktik tedavi ile birlikte intravenöz gansiklovir almasına rağmen CMV pnömonisi nedeniyle nakilden bir yıl sonra kaybedilmiştir. Profilaktik tedavinin hematopoetik kök hücre nakli sonrasında CMV infeksiyonlarının sıklığını azalttığı bilinmekle beraber özellikle CMV reaktivasyonunun bağışıklık sisteminin yeniden yapılanmasına bağlı geç dönemde de görülebileceği akılda tutulmalıdır

CMV Pneumonia After Allogeneic Hematopoetic Stem Cell Transplantation: A Case Report

Cytomegalovirus (CMV) infections, especially pneumonia, after allogeneic stem cell transplantation are frequent infections with high mortality and morbidity. In this report, a 45 year-old male patient with allogeneic stem cell transplantation due to primary myelofibrosis plus Graft versus Host Disease was presented. Our patient died because of CMV pneumonia one year after the transplantation, in spite of prophylactic and intravenous gancyclovir treatment. Although prophylactic treatment decreases the frequency of CMV infections after hematopoetic stem cell transplantations, CMV reactivation at the late phase due to immune reconstitution should be kept in mind

PDF

___

Arda B, Işıkgöz Taşbakan M, Pullukçu H et al. Otolog kemik iliği nakli uygulanan bir hastada gelişen CMV enfeksiyonu, Ege Tıp Derg 2006;45(3):207-9.
Aslan M, Öz Y, Yasemin ÖZ, Akay MO, Akşit F. Evaluation of febrile neutropenia in hematologic malignancy patients, Mediterr J Infect Microb Antimicrob 2014;3:20 http://dx.doi.org/10.5578/mjima.8786
Boeckh M. Current antiviral strategies for control- ling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy, Transpl Infect Dis 1999;1(3):165-78. http://dx.doi.org/10.1034/j.1399-3062.1999.010305.x
Erard V, Guthrie KA, Seo S et al. Reduced morta- lity of cytomegalovirus pneumonia after hemato- poietic cell transplantation due to antiviral the- rapy and changes in transplantation practices, Clin Infect Dis 2015;61(1):31-9. http://dx.doi.org/10.1093/cid/civ215
Guo Z, Chen HR, Liu XD et al. Clinical analysis of cytomegalovirus infection after allogeneic hema- topoietic stem cell transplantation, Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012;20(4):971-4.
Itzykson R, Robin M, Moins-Teisserenc Het al. Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplan- tation, Haematologica 2015;100(1):114-23. http://dx.doi.org/10.3324/haematol.2014.113415
Ljungman P, Perez-Bercoff L, Jonsson J et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation, Haematologica 2006;91(1):78-83.
Marchesi F, Pimpinelli F, Gumenyuk S et al. Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lympho- ma patients: a single-center study, World J Transplant 2015;5(3):129-36. http://dx.doi.org/10.5500/wjt.v5.i3.129
Mori T, Kato J. Cytomegalovirus infection/disea- se after hematopoietic stem cell transplantation, Int J Hematol 2010;91:588-95. http://dx.doi.org/10.1007/s12185-010-0569-x
Nakamae H, Kirby KA, Sandmaier BM et al. Effect of conditioning regimen intensity on CMV infecti- on in allogeneic hematopoietic cell transplantati- on, Biol Blood Marrow Transplant 2009;15(6):694- 703. http://dx.doi.org/10.1016/j.bbmt.2009.02.009
Travi G, Pergam SA. Cytomegalovirus pneumonia in hematopoietic stem cell recipients, J Intensive Care Med 2014;29(4):200-12. http://dx.doi.org/10.1177/0885066613476454